Gadolinium-Based Contrast Agents Market Report 2026

The gadolinium-based contrast agents market size has grown strongly in recent years. It will grow from $1.88 billion in 2025 to $2.0 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing use of magnetic resonance imaging scans, rising burden of chronic diseases, growing demand for early disease diagnosis, expanding hospital radiology departments, and increasing adoption of contrast-enhanced imaging.

The gadolinium-based contrast agents market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2030at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to rising patient volume requiring diagnostic imaging, increasing investments in healthcare infrastructure, a growing number of outpatient imaging centers, expanding insurance coverage for magnetic resonance imaging procedures, and increasing emphasis on early disease screening. Major trends in the forecast period include advancements in magnetic resonance imaging contrast chemistry technologies, increasing research and development in safer gadolinium formulations, development of macrocyclic gadolinium-based contrast agents, innovation in low-dose contrast technologies, and advancement in artificial intelligence-supported imaging analysis systems.

The rising number of magnetic resonance imaging (MRI) scans is expected to propel the growth of the gadolinium-based contrast agents market going forward. Magnetic resonance imaging (MRI) scans are non-invasive diagnostic procedures that use strong magnetic fields and radio waves to generate detailed images of internal organs and tissues. The increasing volume of MRI scans is largely driven by the expanding global geriatric population, which has a higher incidence of chronic diseases requiring precise, non-invasive soft-tissue imaging for accurate diagnosis and treatment planning. Gadolinium-based contrast agents enhance MRI scans by improving the visualization of blood vessels, tumors, and inflamed tissues, thereby supporting more accurate clinical assessment and decision-making. For instance, in December 2024, according to NHS England, a UK-based publicly funded healthcare system, the number of MRI scans in England rose from 361,705 in August 2023 to 365,270 in August 2024, with a rolling 12-month total from September 2023 to August 2024 reaching 4,504,615 scans. Therefore, the rising number of MRI scans is driving the growth of the gadolinium-based contrast agents market.

Major companies operating in the gadolinium-based contrast agents market are focusing on developing advanced product features, such as highly stable macrocyclic agents with elevated relaxivity, to enhance patient safety and improve diagnostic image quality. Highly stable macrocyclic agents with elevated relaxivity are contrast molecules constructed with ring-shaped chelating structures that tightly bind gadolinium ions, minimizing the risk of metal dissociation while generating stronger magnetic resonance signals. This allows for clearer imaging at lower gadolinium doses, addressing safety concerns while maintaining or improving image clarity. For example, in February 2023, Guerbet LLC, a France-based medical imaging company, announced the commercial launch and first patient dosing of Elucirem (gadopiclenol) injection. Elucirem is the first highly stable macrocyclic gadolinium-based contrast agent with the highest relaxivity in its class, enabling use at half the conventional gadolinium dose while delivering high-quality images for detecting lesions in the brain, spine, and associated tissues in adults and children aged two years and older. The agent also enhances contrast between lesions and surrounding tissues by accelerating proton relaxation, representing a significant advancement for neuroradiology imaging.

In September 2024, Zydus Lifesciences Ltd., an India-based innovation-driven healthcare company, entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals Co. Ltd. to commercialize gadolinium-based MRI contrast agents in the US market. Under the terms of the agreement, Viwit Pharmaceuticals will be responsible for the abbreviated new drug application (ANDA) submission, manufacturing, and supply of gadobutrol injection (generic GADAVIST) and gadoterate meglumine injection (generic DOTAREM). Zydus Lifesciences will exclusively market, distribute, and sell these products in the United States following regulatory approval. This collaboration strengthens Zydus’ presence in the US diagnostic imaging segment while leveraging Viwit’s development and manufacturing capabilities to expand access to cost-effective gadolinium-based contrast agents.

Major companies operating in the gadolinium-based contrast agents market are Bayer AG, Siemens Healthineers, Medline Imaging Pvt. Ltd., GE HealthCare Technologies Inc., United Imaging Healthcare, J.B. Chemicals & Pharmaceuticals Ltd., iMax Diagnostic Imaging Ltd., Zhejiang Starry Pharmaceutical Co. Ltd., Trivitron Diagnostic Imaging R&D, Canon Medical Systems Corporation, Beijing Beilu Pharmaceutical Co. Ltd., Unijules Life Sciences Ltd., Vision Pharma Pvt. Ltd., Livealth Biopharma Pvt. Ltd., China Resources Zizhu Pharmaceutical Co. Ltd., Kiran Medical Systems Ltd., Unispire Biopharma Pvt. Ltd.

North America was the largest region in the gadolinium-based contrast agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gadolinium-based contrast agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gadolinium-based contrast agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have influenced the gadolinium-based contrast agent market by increasing import costs for raw gadolinium and advanced chemical components, affecting production timelines and pricing. high-cost segments such as macrocycle gadolinium agents and specialized mri procedures in regions like north america and europe are most impacted. however, tariffs have encouraged local manufacturing and sourcing diversification, potentially fostering domestic innovation and reducing dependency on international supply chains.

Gadolinium-based contrast agents are specialized medical formulations that contain gadolinium ions and are used to enhance the clarity and contrast of tissues during magnetic resonance imaging. Their purpose is to improve the visualization of abnormalities, blood flow, and organ structures, enabling healthcare professionals to produce more accurate diagnostic images.

The main types of gadolinium-based contrast agents include linear and macrocyclic contrast agents. Linear contrast agents contain gadolinium ions in an open-chain structure, improving MRI clarity by enhancing visualization of tissues and blood vessels. MRI procedure types include enhanced scans, cardiac MRI, functional MRI, and whole-body screening. Applications include MRI and MR angiography, with key end users such as hospitals, diagnostic centers, ambulatory surgical centers, and others.

The gadolinium-based contrast agents market consists of sales of gadolinium-containing contrast media used to enhance the visibility of internal organs, tissues, and blood vessels during magnetic resonance imaging procedures. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.